Nanoparticles are rapidly being developed and trialed to overcome several limitations of traditional drug delivery systems and are coming up as a distinct therapeutics for cancer treatment. Conventional chemotherapeutics possess some serious side effects including damage of the immune system and other organs with rapidly proliferating cells due to nonspecific targeting, lack of solubility, and inability to enter the core of the tumors resulting in impaired treatment with reduced dose and with low survival rate. Nanotechnology has provided the opportunity to get direct access of the cancerous cells selectively with increased drug localization and cellular uptake. Nanoparticles can be programmed for recognizing the cancerous cells and giving selective and accurate drug delivery avoiding interaction with the healthy cells. This review focuses on cell recognizing ability of nanoparticles by various strategies having unique identifying properties that distinguish them from previous anticancer therapies. It also discusses specific drug delivery by nanoparticles inside the cells illustrating many successful researches and how nanoparticles remove the side effects of conventional therapies with tailored cancer treatment. 1. Introduction Cancer is one of the most serious fatal diseases in today’s world that kills millions of people every year. It is one of the major health concerns of the 21st century which does not have any boundary and can affect any organ of people from any place [1]. Cancer, the uncontrolled proliferation of cells where apoptosis is greatly disappeared, requires very complex process of treatment. Because of complexity in genetic and phenotypic levels, it shows clinical diversity and therapeutic resistance. A variety of approaches are being practiced for the treatment of cancer each of which has some significant limitations and side effects [2]. Cancer treatment includes surgical removal, chemotherapy, radiation, and hormone therapy. Chemotherapy, a very common treatment, delivers anticancer drugs systemically to patients forquenching the uncontrolled proliferation of cancerous cells [3]. Unfortunately, due to nonspecific targeting by anticancer agents, many side effects occur and poor drug delivery of those agents cannot bring out the desired outcome in most of the cases. Cancer drug development involves a very complex procedure which is associated with advanced polymer chemistry and electronic engineering. The main challenge of cancer therapeutics is to differentiate the cancerous cells and the normal body cells. That is why the main
References
[1]
D. J. Bharali and S. A. Mousa, “Emerging nanomedicines for early cancer detection and improved treatment: current perspective and future promise,” Pharmacology and Therapeutics, vol. 128, no. 2, pp. 324–335, 2010.
[2]
G. Zhao and B. L. Rodriguez, “Molecular targeting of liposomal nanoparticlesto tumor microenvironment,” International Journal of Nanomedicine, vol. 8, pp. 61–71, 2013.
[3]
N. R. Jabir, S. Tabrez, G. M. Ashraf, S. Shakil, G. A. Damanhouri, and M. A. Kamal, “Nanotechnology-based approaches in anticancer research,” International Journal of Nanomedicine, vol. 7, pp. 4391–4408, 2012.
[4]
S. A. Mousa and D. J. Bharali, “Nanotechnology-based detection and targeted therapy in cancer: nano-bio paradigms and applications,” Cancers, vol. 3, no. 3, pp. 2888–2903, 2011.
[5]
D. Peer, J. M. Karp, S. Hong, O. C. Farokhzad, R. Margalit, and R. Langer, “Nanocarriers as an emerging platform for cancer therapy,” Nature Nanotechnology, vol. 2, no. 12, pp. 751–760, 2007.
[6]
Y. Malam, M. Loizidou, and A. M. Seifalian, “Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer,” Trends in Pharmacological Sciences, vol. 30, no. 11, pp. 592–599, 2009.
[7]
K. B. Sutradhar and M. L. Amin, “Nanoemulsions: increasing possibilities in drug delivery,” European Journal of Nanomedicine, vol. 5, no. 2, pp. 97–110, 2013.
[8]
N. P. Praetorius and T. K. Mandal, “Engineered nanoparticles in cancer therapy,” Recent Patents on Drug Delivery & Formulation, vol. 1, no. 1, pp. 37–51, 2007.
[9]
K. Park, “Nanotechnology: what it can do for drug delivery,” Journal of Controlled Release, vol. 120, no. 1-2, pp. 1–3, 2007.
[10]
L. A. Nagahara, J. S. H. Lee, L. K. Molnar et al., “Strategic workshops on cancer nanotechnology,” Cancer Research, vol. 70, no. 11, pp. 4265–4268, 2010.
[11]
K. T. Nguyen, “Targeted nanoparticles for cancer therapy: promises and challenges,” Journal of Nanomedicine & Nanotechnology, vol. 2, no. 5, article 103e, 2011.
[12]
A. Coates, S. Abraham, and S. B. Kaye, “On the receiving end—patient perception of the side-effects of cancer chemotherapy,” European Journal of Cancer and Clinical Oncology, vol. 19, no. 2, pp. 203–208, 1983.
[13]
I. F. Tannock, C. M. Lee, J. K. Tunggal, D. S. M. Cowan, and M. J. Egorin, “Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy,” Clinical Cancer Research, vol. 8, no. 3, pp. 878–884, 2002.
[14]
R. Krishna and L. D. Mayer, “Multidrug resistance (MDR) in cancerMechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs,” European Journal of Pharmaceutical Sciences, vol. 11, no. 4, pp. 265–283, 2000.
[15]
M. Links and R. Brown, “Clinical relevance of the molecular mechanisms of resistance to anti-cancer drugs,” Expert Reviews in Molecular Medicine, vol. 1999, pp. 1–21, 1999.
[16]
M. M. Gottesman, C. A. Hrycyna, P. V. Schoenlein, U. A. Germann, and I. Pastan, “Genetic analysis of the multidrug transporter,” Annual Review of Genetics, vol. 29, pp. 607–649, 1995.
[17]
M. E. Davis, Z. Chen, and D. M. Shin, “Nanoparticle therapeutics: an emerging treatment modality for cancer,” Nature Reviews Drug Discovery, vol. 7, no. 9, pp. 771–782, 2008.
[18]
X. Guo and F. C. Szoka Jr., “Chemical approaches to triggerable lipid vesicles for drug and gene delivery,” Accounts of Chemical Research, vol. 36, no. 5, pp. 335–341, 2003.
[19]
S. Nie, Y. Xing, G. J. Kim, and J. W. Simons, “Nanotechnology applications in cancer,” Annual Review of Biomedical Engineering, vol. 9, pp. 257–288, 2007.
[20]
K. Cho, X. Wang, S. Nie, Z. Chen, and D. M. Shin, “Therapeutic nanoparticles for drug delivery in cancer,” Clinical Cancer Research, vol. 14, no. 5, pp. 1310–1316, 2008.
[21]
M. V. Yezhelyev, X. Gao, Y. Xing, A. Al-Hajj, S. Nie, and R. M. O'Regan, “Emerging use of nanoparticles in diagnosis and treatment of breast cancer,” Lancet Oncology, vol. 7, no. 8, pp. 657–667, 2006.
[22]
R. Duncan, “Polymer conjugates as anticancer nanomedicines,” Nature Reviews Cancer, vol. 6, no. 9, pp. 688–701, 2006.
[23]
M. Ferrari, “Cancer nanotechnology: opportunities and challenges,” Nature Reviews Cancer, vol. 5, no. 3, pp. 161–171, 2005.
[24]
D. A. LaVan, T. McGuire, and R. Langer, “Small-scale systems for in vivo drug delivery,” Nature Biotechnology, vol. 21, no. 10, pp. 1184–1191, 2003.
[25]
I. Brigger, C. Dubernet, and P. Couvreur, “Nanoparticles in cancer therapy and diagnosis,” Advanced Drug Delivery Reviews, vol. 54, no. 5, pp. 631–651, 2002.
[26]
S. I. Jeon, J. H. Lee, J. D. Andrade, and P. G. De Gennes, “Protein-surface interactions in the presence of polyethylene oxide. I. Simplified theory,” Journal of Colloid and Interface Science, vol. 142, no. 1, pp. 149–158, 1991.
[27]
P. Tallury, S. Kar, S. Bamrungsap, Y.-F. Huang, W. Tan, and S. Santra, “Ultra-small water-dispersible fluorescent chitosan nanoparticles: synthesis, characterization and specific targeting,” Chemical Communications, vol. 17, pp. 2347–2349, 2009.
[28]
M. F. Francis, M. Cristea, and F. M. Winnik, “Polymeric micelles for oral drug delivery: why and how,” Pure and Applied Chemistry, vol. 76, no. 7-8, pp. 1321–1335, 2004.
[29]
G. Storm, S. O. Belliot, T. Daemen, and D. D. Lasic, “Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system,” Advanced Drug Delivery Reviews, vol. 17, no. 1, pp. 31–48, 1995.
[30]
V. P. Torchilin and V. S. Trubetskoy, “Which polymers can make nanoparticulate drug carriers long-circulating?” Advanced Drug Delivery Reviews, vol. 16, no. 2-3, pp. 141–155, 1995.
[31]
G. A. Mansoori, P. Mohazzabi, P. McCormack, and S. Jabbari, “Nanotechnology in cancer prevention, detection and treatment: bright future lies ahead,” World Review of Science, Technology and Sustainable Development, vol. 4, no. 2-3, pp. 226–257, 2007.
[32]
J. Sudimack and R. J. Lee, “Targeted drug delivery via the folate receptor,” Advanced Drug Delivery Reviews, vol. 41, no. 2, pp. 147–162, 2000.
[33]
J. F. Kukowska-Latallo, K. A. Candido, Z. Cao et al., “Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer,” Cancer Research, vol. 65, no. 12, pp. 5317–5324, 2005.
[34]
G. Russell-Jones, K. McTavish, J. McEwan, and B. Thurmond, “Increasing the tumoricidal activity of daunomycin-pHPMA conjugates using vitamin B12 as a targeting agent,” Journal of Cancer Research Updates, vol. 1, no. 2, pp. 1–6, 2012.
[35]
G. L. Zwicke, G. A. Mansoori, and C. J. Jeffery, “Utilizing the folate receptor for active targeting of cancer nanotherapeutics,” Nano Reviews, vol. 3, Article ID 18496, 3 pages, 2012.
[36]
H. S. Yoo and T. G. Park, “Folate-receptor-targeted delivery of doxorubicin nano-aggregates stabilized by doxorubicin-PEG-folate conjugate,” Journal of Controlled Release, vol. 100, no. 2, pp. 247–256, 2004.
[37]
M. Kawamoto, T. Horibe, M. Kohno, and K. Kawakami, “A novel transferrin receptor-targeted hybrid peptide disintegrates cancer cell membrane to induce rapid killing of cancer cells,” BMC Cancer, vol. 11, article 359, 2011.
[38]
T. R. Daniels, B. Bernabeu, J. A. Rodríguez, et al., “Transferrin receptors and the targeted delivery of therapeutic agents against cancer,” Biochimica et Biophysica Acta, vol. 1820, no. 3, pp. 291–317, 2012.
[39]
N. C. Bellocq, S. H. Pun, G. S. Jensen, and M. E. Davis, “Transferrin-containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery,” Bioconjugate Chemistry, vol. 14, no. 6, pp. 1122–1132, 2003.
[40]
C. R. Dass and P. F. M. Choong, “Targeting of small molecule anticancer drugs to the tumour and its vasculature using cationic liposomes: lessons from gene therapy,” Cancer Cell International, vol. 6, article 17, 2006.
[41]
H. K. Sun, H. J. Ji, H. L. Soo, W. K. Sung, and G. P. Tae, “LHRH receptor-mediated delivery of siRNA using polyelectrolyte complex micelles self-assembled from siRNA-PEG-LHRH conjugate and PEI,” Bioconjugate Chemistry, vol. 19, no. 11, pp. 2156–2162, 2008.
[42]
S. S. Dharap, Y. Wang, P. Chandna et al., “Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 36, pp. 12962–12967, 2005.
[43]
http://web.mit.edu/newsoffice/2006/prostate.html.
[44]
T. M. Allen, “Ligand-targeted therapeutics in anticancer therapy,” Nature Reviews Cancer, vol. 2, no. 10, pp. 750–763, 2002.
[45]
P. Carter, “Improving the efficacy of antibody-based cancer therapies,” Nature Reviews Cancer, vol. 1, no. 2, pp. 118–129, 2001.
[46]
W. H. Ouwehand, R. Finnern, B. D. Gorick, et al., “Selection of internalizing antibodies for drug delivery,” Methods in Molecular Biology, vol. 248, pp. 201–208, 2004.
[47]
J. D. Marks, W. H. Ouwehand, J. M. Bye et al., “Human antibody fragments specific for human blood group antigens from a phage display library,” Bio/Technology, vol. 11, no. 10, pp. 1145–1149, 1993.
[48]
B. Liu, F. Conrad, M. R. Cooperberg, D. B. Kirpotin, and J. D. Marks, “Mapping tumor epitope space by direct selection of single-chain Fv antibody libraries on prostate cancer cells,” Cancer Research, vol. 64, no. 2, pp. 704–710, 2004.
[49]
D. Peer, P. Zhu, C. V. Carman, J. Lieberman, and M. Shimaoka, “Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 10, pp. 4095–4100, 2007.
[50]
H. Wartlick, K. Michaelis, S. Balthasar, K. Strebhardt, J. Kreuter, and K. Langer, “Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells,” Journal of Drug Targeting, vol. 12, no. 7, pp. 461–471, 2004.
[51]
S. Sudarshan, D. H. Holman, M. L. Hyer, C. Voelkel-Johnson, J.-Y. Dong, and J. S. Norris, “In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancer,” Cancer Gene Therapy, vol. 12, no. 1, pp. 12–18, 2005.
[52]
O. Micheau, E. Solary, A. Hammann, F. Martin, and M.-T. Dimanche-Boitrel, “Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity,” Journal of the National Cancer Institute, vol. 89, no. 11, pp. 783–789, 1997.
[53]
G. N. Naumov, L. A. Akslen, and J. Folkman, “Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch,” Cell Cycle, vol. 5, no. 16, pp. 1779–1787, 2006.
[54]
M. A. J. Chaplain, “Mathematical modelling of angiogenesis,” Journal of Neuro-Oncology, vol. 50, no. 1-2, pp. 37–51, 2000.
[55]
J. Folkman, “Incipient angiogenesis,” Journal of the National Cancer Institute, vol. 92, no. 2, pp. 94–95, 2000.
[56]
N. Weidner, J. Folkman, F. Pozza et al., “Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma,” Journal of the National Cancer Institute, vol. 84, no. 24, pp. 1875–1887, 1992.
[57]
D. Fukumura and R. K. Jain, “Imaging angiogenesis and the microenvironment,” APMIS, vol. 116, no. 7-8, pp. 695–715, 2008.
[58]
M. Dhanabal, M. Jeffers, and W. J. LaRochelle, “Anti-angiogenic therapy as a cancer treatment paradigm,” Current Medicinal Chemistry, vol. 5, no. 2, pp. 115–130, 2005.
[59]
N. Weidner, J. P. Semple, W. R. Welch, and J. Folkman, “Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma,” The New England Journal of Medicine, vol. 324, no. 1, pp. 1–8, 1991.
[60]
J. Folkman, “Fundamental concepts of the angiogenic process,” Current Molecular Medicine, vol. 3, no. 7, pp. 643–651, 2003.
[61]
D. Banerjee, R. Harfouche, and S. Sengupta, “Nanotechnology-mediated targeting of tumor angiogenesis,” Vascular Cell, vol. 3, article 3, 2011.
[62]
N. Boudreau and C. Myers, “Breast cancer-induced angiogenesis: multiple mechanisms and the role of the microenvironment,” Breast Cancer Research, vol. 5, no. 3, pp. 140–146, 2003.
[63]
N. N. Khodarev, J. Yu, E. Labay et al., “Tumour-endothelium interactions in co-culture: coordinated changes of gene expression profiles and phenotypic properties of endothelial cells,” Journal of Cell Science, vol. 116, no. 6, pp. 1013–1022, 2003.
[64]
J. S. Desgrosellier and D. A. Cheresh, “Integrins in cancer: biological implications and therapeutic opportunities,” Nature Reviews Cancer, vol. 10, no. 1, pp. 9–22, 2010.
[65]
Y. Pan, H. Ding, L. Qin, X. Zhao, J. Cai, and B. Du, “Gold nanoparticles induce nanostructural reorganization of VEGFR2 to repress angiogenesis,” Journal of Biomedical Nanotechnology, vol. 9, no. 10, pp. 1746–1756, 2013.
[66]
S. A. Anderson, R. K. Rader, W. F. Westlin, et al., “Magnetic resonance contrast enhancement of neovasculature with alpha(v)beta(3)-targeted nanoparticles,” Magnetic Resonance in Medicine, vol. 44, pp. 433–439, 2000.
[67]
J. H. Park, S. Kwon, J.-O. Nam et al., “Self-assembled nanoparticles based on glycol chitosan bearing 5β-cholanic acid for RGD peptide delivery,” Journal of Controlled Release, vol. 95, no. 3, pp. 579–588, 2004.
[68]
E. A. Waters, J. Chen, X. Yang et al., “Detection of targeted perfluorocarbon nanoparticle binding using 19F diffusion weighted MR spectroscopy,” Magnetic Resonance in Medicine, vol. 60, no. 5, pp. 1232–1236, 2008.
[69]
P. M. Winter, A. M. Morawski, S. D. Caruthers et al., “Molecular imaging of angiogenesis in early-stage atherosclerosis with αvβ3-integrin-targeted nanoparticles,” Circulation, vol. 108, no. 18, pp. 2270–2274, 2003.
[70]
J. Li, J. Ji, L. M. Holmes et al., “Fusion protein from RGD peptide and Fc fragment of mouse immunoglobulin G inhibits angiogenesis in tumor,” Cancer Gene Therapy, vol. 11, no. 5, pp. 363–370, 2004.
[71]
E. Ruoslahti, “Cell adhesion and tumor metastasis,” Princess Takamatsu Symposia, vol. 24, pp. 99–105, 1994.
[72]
N. Ferrara, “VEGF as a therapeutic target in cancer,” Oncology, vol. 69, no. 3, pp. 11–16, 2005.
[73]
D. F. Baban and L. W. Seymour, “Control of tumour vascular permeability,” Advanced Drug Delivery Reviews, vol. 34, no. 1, pp. 109–119, 1998.
[74]
S. K. Hobbs, W. L. Monsky, F. Yuan et al., “Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 8, pp. 4607–4612, 1998.
[75]
P. Rubin and G. Casarett, “Microcirculation of tumors Part I: anatomy, function, and necrosis,” Clinical Radiology, vol. 17, no. 3, pp. 220–229, 1966.
[76]
P. Shubik, “Vascularization of tumors: a review,” Journal of Cancer Research and Clinical Oncology, vol. 103, no. 3, pp. 211–226, 1982.
[77]
R. K. Jain and T. Stylianopoulos, “Delivering nanomedicine to solid tumors,” Nature Reviews Clinical Oncology, vol. 7, no. 11, pp. 653–664, 2010.
[78]
S. H. Jang, M. G. Wientjes, D. Lu, and J. L.-S. Au, “Drug delivery and transport to solid tumors,” Pharmaceutical Research, vol. 20, no. 9, pp. 1337–1350, 2003.
[79]
H. Maeda, “The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting,” Advances in Enzyme Regulation, vol. 41, pp. 189–207, 2001.
[80]
H. Maeda, J. Wu, T. Sawa, Y. Matsumura, and K. Hori, “Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review,” Journal of Controlled Release, vol. 65, no. 1-2, pp. 271–284, 2000.
[81]
F. Yuan, “Transvascular drug delivery in solid tumors,” Seminars in Radiation Oncology, vol. 8, no. 3, pp. 164–175, 1998.
A. K. Patri, J. F. Kukowska-Latallo, and J. R. Baker Jr., “Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex,” Advanced Drug Delivery Reviews, vol. 57, no. 15, pp. 2203–2214, 2005.
[87]
N. Desai, “Challenges in development of nanoparticle-based therapeutics,” The AAPS Journal, vol. 14, no. 2, pp. 282–294, 2012.
[88]
C. E. Soma, C. Dubernet, D. Bentolila, S. Benita, and P. Couvreur, “Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles,” Biomaterials, vol. 21, no. 1, pp. 1–7, 2000.
[89]
M. L. Amin, “P-glycoprotein inhibition for optimal drug delivery,” Drug Target Insights, vol. 7, pp. 27–34, 2013.
[90]
H. Matsuo, M. Wakasugi, H. Takanaga et al., “Possibility of the reversal of multidrug resistance and the avoidance of side effects by liposomes modified with MRK-16, a monoclonal antibody to P-glycoprotein,” Journal of Controlled Release, vol. 77, no. 1-2, pp. 77–86, 2001.
[91]
S. Danson, D. Ferry, V. Alakhov et al., “Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer,” British Journal of Cancer, vol. 90, no. 11, pp. 2085–2091, 2004.
[92]
E. V. Batrakova, T. Y. Dorodnych, E. Y. Klinskii et al., “Anthracycline antibiotics non-covalently incorporated into the block copolymer micelles: in vivo evaluation of anti-cancer activity,” British Journal of Cancer, vol. 74, no. 10, pp. 1545–1552, 1996.
[93]
D. Goren, A. T. Horowitz, D. Tzemach, M. Tarshish, S. Zalipsky, and A. Gabizon, “Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump,” Clinical Cancer Research, vol. 6, no. 5, pp. 1949–1957, 2000.
[94]
J. Kos, N. Obermajer, B. Doljak, P. Kocbek, and J. Kristl, “Inactivation of harmful tumour-associated proteolysis by nanoparticulate system,” International Journal of Pharmaceutics, vol. 381, no. 2, pp. 106–112, 2009.
[95]
A. Cirstoiu-Hapca, F. Buchegger, L. Bossy, M. Kosinski, R. Gurny, and F. Delie, “Nanomedicines for active targeting: physico-chemical characterization of paclitaxel-loaded anti-HER2 immunonanoparticles and in vitro functional studies on target cells,” European Journal of Pharmaceutical Sciences, vol. 38, no. 3, pp. 230–237, 2009.
[96]
Y. B. Patil, U. S. Toti, A. Khdair, L. Ma, and J. Panyam, “Single-step surface functionalization of polymeric nanoparticles for targeted drug delivery,” Biomaterials, vol. 30, no. 5, pp. 859–866, 2009.
[97]
W. Yang, Y. Cheng, T. Xu, X. Wang, and L.-P. Wen, “Targeting cancer cells with biotin-dendrimer conjugates,” European Journal of Medicinal Chemistry, vol. 44, no. 2, pp. 862–868, 2009.
[98]
Y. Liu, K. Li, J. Pan, B. Liu, and S.-S. Feng, “Folic acid conjugated nanoparticles of mixed lipid monolayer shell and biodegradable polymer core for targeted delivery of Docetaxel,” Biomaterials, vol. 31, no. 2, pp. 330–338, 2010.
[99]
O. Taratula, O. B. Garbuzenko, P. Kirkpatrick et al., “Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery,” Journal of Controlled Release, vol. 140, no. 3, pp. 284–293, 2009.
[100]
Y. Patil, T. Sadhukha, L. Ma, and J. Panyam, “Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance,” Journal of Controlled Release, vol. 136, no. 1, pp. 21–29, 2009.
[101]
E. Brewer, J. Coleman, and A. Lowman, “Emerging technologies of polymeric nanoparticles in cancer drug delivery,” Journal of Nanomaterials, vol. 2011, Article ID 408675, 2011.
[102]
C. C. Anajwala, G. K. Jani, and S. M. V. Swamy, “Current trends of nanotechnology for cancer therapy,” International Journal of Pharmaceutical Sciences and Nanotechnology, vol. 3, pp. 1043–1056, 2010.
[103]
B. Haley and E. Frenkel, “Nanoparticles for drug delivery in cancer treatment,” Urologic Oncology, vol. 26, no. 1, pp. 57–64, 2008.
[104]
D. Lasic, “Doxorubicin in sterically stabilized,” Nature, vol. 380, no. 6574, pp. 561–562, 1996.
[105]
Y. Matsumura, T. Hamaguchi, T. Ura et al., “Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin,” British Journal of Cancer, vol. 91, no. 10, pp. 1775–1781, 2004.
[106]
J. Kreuter and T. Higuchi, “Improved delivery of methoxsalen,” Journal of Pharmaceutical Sciences, vol. 68, no. 4, pp. 451–454, 1979.
[107]
D. Papahadjopoulos, T. M. Allen, A. Gabizon et al., “Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 24, pp. 11460–11464, 1991.
[108]
D. Peer and R. Margalit, “Loading mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models,” International Journal of Cancer, vol. 108, no. 5, pp. 780–789, 2004.
[109]
R. E. Eliaz and F.C. Szoka Jr., “Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells,” Cancer Research, vol. 61, no. 6, pp. 2592–2601, 2001.
[110]
S. R. Grobmyera, G. Zhoua, L. G. Gutweina, N. Iwakumab, P. Sharmac, and S. N. Hochwalda, “Nanoparticle delivery for metastatic breast cancer,” Nanomedicine: Nanotechnology, Biology, and Medicine, vol. 8, pp. S21–S30, 2012.
[111]
Y. Liu, H. Miyoshi, and M. Nakamura, “Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles,” International Journal of Cancer, vol. 120, no. 12, pp. 2527–2537, 2007.
[112]
Y. Fukumori and H. Ichikawa, “Nanoparticles for cancer therapy and diagnosis,” Advanced Powder Technology, vol. 17, no. 1, pp. 1–28, 2006.
[113]
M. B. Yatvin, W. Kreutz, B. A. Horwitz, and M. Shinitzky, “pH-sensitive liposomes: possible clinical implications,” Science, vol. 210, no. 4475, pp. 1253–1255, 1980.
[114]
S. K. Huang, P. R. Stauffer, K. Hong et al., “Liposomes and hyperthermia in mice: increased tumor uptake and therapeutic efficacy of doxorubicin in sterically stabilized liposomes,” Cancer Research, vol. 54, no. 8, pp. 2186–2191, 1994.
[115]
E. S. Kawasaki and A. Player, “Nanotechnology, nanomedicine, and the development of new, effective therapies for cancer,” Nanomedicine, vol. 1, no. 2, pp. 101–109, 2005.
[116]
A. Z. Wang, R. Langer, and O. C. Farokhzad, “Nanoparticle delivery of cancer drugs,” Annual Review of Medicine, vol. 63, pp. 185–198, 2012.
[117]
G. A. Hughes, “Nanostructure-mediated drug delivery,” Nanomedicine: Nanotechnology, Biology and Medicine, vol. 1, pp. 22–30, 2005.
[118]
S. M. Moghimi, A. C. Hunter, and J. C. Murray, “Nanomedicine: current status and future prospects,” The FASEB Journal, vol. 19, no. 3, pp. 311–330, 2005.
[119]
C. Kojima, K. Kono, K. Maruyama, and T. Takagishi, “Synthesis of polyamidoamine dendrimers having poly(ethylene glycol) grafts and their ability to encapsulate anticancer drugs,” Bioconjugate Chemistry, vol. 11, no. 6, pp. 910–917, 2000.
[120]
Z. Liu, K. Chen, C. Davis et al., “Drug delivery with carbon nanotubes for in vivo cancer treatment,” Cancer Research, vol. 68, no. 16, pp. 6652–6660, 2008.
[121]
A. Bianco, K. Kostarelos, and M. Prato, “Applications of carbon nanotubes in drug delivery,” Current Opinion in Chemical Biology, vol. 9, no. 6, pp. 674–679, 2005.
